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Abstract
Background: Healing of bone defects is a dynamic and orchestrated process that relies on multiple growth factors
and cell types. Bone morphogenetic protein 2 (BMP2) is a key growth factor for bone healing, which stimulates
mesenchymal stem cells to differentiate into osteoblasts. Betulinic acid (BetA) is a natural pentacyclic triterpenoid from
plants. This study aimed to examine combinatory effects of BetA and BMP2 on ectopic bone generation in mice.
Results: In MC3T3-E1 preosteoblast culture, 10–15 μM of BetA increased the alkaline phosphatase (ALP) activity and
expression levels of osteogenic marker genes without the decreased cell viability. In addition, BetA synergistically
enhanced BMP2-induced gene expressions and mineralization with the enhancement of phosphorylation of Smad1/5/8
and p38. In an in vivo ectopic bone formation model, combination of BetA (50 μg) and BMP2 (3 μg) resulted in increases
in the amount of new bone generation, compared with treatment with BMP2 alone. Histological studies showed that
bone generation with cortical and trabecular structures was resulted from the combination of BetA and BMP2.
Conclusion: BetA can enhance in vivo osteogenic potentials of BMP2, possibly via stimulating Smad 1/5/8 and p38
pathways, and combination of both agents can be considered as a therapeutic strategy for bone diseases.
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Background
An insufficient amount of bone is still considered to be
one of the major problems associated with orthopedic
procedures or neurosurgery as well as oral and maxillo-
facial surgery, and various approaches are being devel-
oped to overcome this problem [1, 2]. At present,
autologous bone graft surgery is a frequently employed
approach, which is used to supplement the missing
bone. However, autografts require additional invasive
procedures and are often painful with limited access to
the graft site. Additional complications may include in-
fection, delayed time to healing, morbidity to the donor
site as well as the high cost of an operation [3]. In order
to address these drawbacks, several families of drugs de-
signed to up-regulate bone formation and increase bone
mass have been developed [4]. In a few of Asian coun-
tries such as Korea, China and Japan, herbal medicines
have been widely investigated for their clinical potential
to treat bone disease [5, 6]. In fact, some herbal extracts
have demonstrated their bone-forming or osteoprotec-
tive effects in cell cultures or animal models [5–7].
Betulinic acid (3β, hydroxy-lup-20 (29)-en-28-oic acid;
BetA) is a naturally occurring pentacyclic triterpenoid
found in many kinds of fruits, vegetables and most
abundant in the Sambucus williamsii Hance tree [8, 9].
In China, stem and ramulus of the tree has been used
traditionally as an herbal remedy for osteoporosis, joint
diseases and bone fracture [10]. BetA has been intro-
duced to have anti-inflammatory and anti-cancer activ-
ities in various experimental models [11, 12]. A recent
study revealed that BetA also has potent action on
osteoblast differentiation and mineralization by the
BMP/Smad/Runx2 signaling pathways [9]. However,
the study only demonstrated that BetA positively
influenced osteogenic functions in MC3T3-E1 preos-
teoblasts in an in vitro model.
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Some growth factors including vascular endothelial
growth factor (VEGF), transforming growth factor beta
(TGF-β), platelet-derived growth factor (PDGF), and bone
morphogenetic proteins (BMPs) are highly expressed dur-
ing the bone healing cascade [13, 14]. The bone morpho-
genetic protein 2 (BMP2) has been well-established as a
very strong inducer of osteogenesis that plays a critical role
during bone formation and remodeling [15]. Furthermore,
animal and human studies have shown that treatment with
BMP2 results in efficacious bone regeneration and healing
with restoration of function [16–18]. However, although
the use of BMP2 enhances bone fracture healing, the
physiological disadvantages of a short biological half-
life combined with rapid local clearance and the re-
quirement for high doses might lead to adverse effects
such as osteoclastogenesis, immunological reactions,
and edema [14, 19–22]. In addition, the BMP2 protein
is not only costly but also undergoes rapid degradation
after an initial burst release. In order to minimize risks
and reduce the dose required, the effect of BMP2 on
bone formation has been investigated in conjunction
with a variety of factors including chemical agents,
stem cells and genes [13, 23, 24]. Moreover, a combin-
ation therapy of anti-osteoporotic agents with BMPs
has also been evaluated in the repair of bone defects
and induced bone formation [13].
This study investigated the effect of a combination of
BetA and BMP2, as compared to BMP2 alone, on ec-
topic bone formation in mice. We hypothesized that
combined delivery of BetA and BMP2 could enhance
bone formation and better stimulate the bone healing
effects. Our data showed a potential synergy in vivo with
a combination of BetA and BMP2; the combination
significantly enhanced ectopic bone formation compared
to an implant with both single factor, and enhanced
osteogenic differentiation through activation of phos-
phorylated Smad1/5/8 and p38 signaling pathways.
Methods
Recombinant proteins and materials
Betulinic acid (BetA) was purchased from Sigma-Aldrich
(St. Louis, MO, USA) and dissolved in 0.1 % DMSO.
Recombinant human bone morphogenetic protein 2
(BMP2) was purchased from Cowellmedi (Seoul, Korea).
The absorbable collagen sponge CollaDerm was obtained
from Bioland (Ochang, Korea).
Cell cultures
MC3T3-E1 pre-osteoblasts were cultured in α-minimal
essential medium (α-MEM; Invitrogen, Carlsbad, CA,
USA) supplemented with 10 % fetal bovine serum (FBS;
Gibco-BRL, Grand Island, USA) and 1 % penicillin/
streptomycin (Invitrogen), and incubated at 37 °C in a
humidified atmosphere of 5 % CO2. For osteogenic
differentiation, 50 μg/ml ascorbic acid and 5 mM β-
glycerophosphate were added into the culture medium
in the presence or absence of BetA and/or BMP2.
Cell viability assay
The WST-1 assay kit (EZ-CytoX, Daeil Lab Service CO.,
Seoul, Korea) was used according to the manufacturer's
instructions. Briefly, cells were seeded into 96-well plates
and incubated in serum-free medium for 24 h. Cells
were then stimulated for 24 h with BetA at concentra-
tions ranging from 5 μM to 30 μM, and assays were per-
formed by adding WST-1 directly to the culture. The
absorbance of the wells was measured at 540 nm by
using spectrophotometry (Multiskan GO, Thermo Scien-
tific, Waltham, USA).
Total RNA extraction and RT-PCR
Total RNA was isolated from the cultured cells using TRI-
zol reagent (Invitrogen) according to the manufacturer’s
instructions and cDNA was synthesized from the ex-
tracted total RNA using random primers and reverse tran-
scriptase (Invitrogen). PCR was then used to amplify the
osteogenic markers; mouse alkaline phosphatase (ALP),
mouse bone sialoprotein (BSP), mouse osteocalcin (OC),
mouse bone morphogenetic protein 2 (BMP2), and mouse
glyceraldehyde-3-phophate dehydrogenase (GAPDH). The
primer sequences used for PCR amplification were as fol-
lows: ALP (F) 5′-TACATTCCCCATGTGATGGC-3′ and
(R) 5′-ACCTCTCCCTTGAGTGTGGG-3′, BSP (F) 5′-G
GAGGGGGCTTCACTGAT-3′ and (R) 5′-AACAATCC
GTGCCACCA-3′, BMP2 (F) 5′-AGCTGCAAGAGAC
ACCCTTT-3′ and (R) 5′- CATGCCTTAGGGATTTTG
GA-3′, OC (F) 5′-CTCCTGAGTCTGACAAAGCCTT-3′
and (R) 5′-GCTGTGACATCCATTACTTGC-3′, and
GAPDH, (F) 5′-ACCACAGTCCATGCCATCAC-3′ and
(R) 5′-TCCACCACCCTGTTGCTGTA-3′. Each reaction
consisted of an initial denaturation step at 94 °C for
1 min, followed by a three-stage cycle: denaturation
at 94 °C for 30 s, annealing at a temperature opti-
mized for each primer pair for 30 s, and extension at
72 °C for 30 s. After the requisite number of cycles
(25–30 cycles), the reactions underwent a final exten-
sion at 72 °C for 5 min.
Alkaline phosphatase (ALP) activity and matrix
mineralization
For ALP activity, cultured cells were fixed with 70 % etha-
nol, rinsed three times with deionized water, and then
treated for 15 min with BCIP®/NBT solution (Sigma
Aldrich, St. Louis, MO, USA). The stained cultures were
photographed. For matrix mineralization analysis, alizarin
red staining was performed using the manufacturer’s pro-
tocols. Briefly, cultured cells were fixed with 70 % ethanol
for 60 min, rinsed three times with deionized water, and
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reacted with 40 mM alizarin red stain solution (pH 4.2)
for 15 min. After washing with phosphate-buffered sa-
line (PBS) for 15 min, the stained cultures were then
photographed. To quantify the matrix mineralization,
stains were extracted with 10 % (w/v) cetylpyridinium
chloride and the absorbance was measured against a
standard solution by using a spectrophotometer
(Thermo Scientific) at 540 nm.
Western blot analysis
The MC3T3-E1 preosteoblast cells were cultured in
medium supplemented with BetA (10 μM) and/or BMP2
(200 ng/ml). After 5 to 10 min, cells were harvested in a
lysis buffer (Cell Signaling, Beverly, MA, USA) and the
protein concentration was determined by the BCA assay
reagent (Bio-Rad Laboratories, Hercules, CA, USA). Pro-
teins were resolved on 10 % SDS-PAGE and transferred
to a PVDF membrane. After blocking in 5 % skim milk
in Tris-buffered saline with 0.1 % Tween-20 (TBS-T),
the membrane was incubated overnight at 4 °C with spe-
cific primary antibodies for phospho-Smad1/5/8, total
Smad, phospho-Erk1/2, total Erk1/2, phospho-p38, total
p38 (Cell Signaling, Beverly, MA, USA) diluted 1:1,000
in 5 % skim milk in TBS-T. After washing, the blots
were incubated for 2 h with anti-rabbit horseradish-
peroxidase-conjugated antibody (Promega, Madison, WI,
USA) diluted 1:3,000 in TBS-T. Signals were detected by
an enhanced chemiluminescence reagent (Santa Cruz
Biotech, CA, USA) and a LAS-4000 lumino-image
analyzer system (Fujifilm, Tokyo, Japan).
Animal surgery and experimental design
All animal studies were reviewed and approved by the
Animal Ethics Committee of Chonnam National Univer-
sity (No. CNU-IACUC-YB-2014-35). Six week-old male
C57BL/6 mice (Daehan Biolink, Eumseong, Korea; 20 to
25 g body weight) were divided randomly into five
groups (five mice per group). After inducing general
anesthesia by intraperitoneal injection of a mixture of
Zoletil (30 mg/kg; Virbac Lab, Carros, France) and Rom-
pun (10 mg/kg; Bayer Korea Ltd, Ansan, Korea) each
mouse was shaved, and the dorsum prepped with
povidone-iodine (Sung Kwang Pharm Ltd, Cheonan,
Korea) and ethanol. A sagittal incision (0.8 to 1.0 cm)
was made on the back, and then a subcutaneous pocket
was formed using blunt dissecting.
Absorbable stable hemostatic collagen sponges (Colladerm,
Bioland, Ochang, Korea) cut into pieces (approximately 10 ×
10 × 3 mm3) under semi-sterile conditions, were used as a
carrier to deliver BetA and BMP2. For the control
group, the sponges were impregnated with 50 μl of
0.1 % DMSO; for the BMP2 group, 3 μg of BMP2; for
the BetA group, 25 or 50 μg of BetA; for the first com-
bination group, 3 μg of BMP2 and 25 μg of BetA; and
for the second combination group, 3 μg of BMP2 and
50 μg of BetA. All additions were brought to a total vol-
ume of 100 μl in PBS and the sponges were implanted
into the subcutaneous pocket.
The animals were sacrificed by CO2 asphyxiation at
4 weeks after the implantation. Specimens were carefully
dissected and harvested from each group, fixed in 10 %
neutral-buffered formalin solution for 24 h, and subse-
quently transferred into 70 % ethyl alcohol for further
radiographic and histology studies.
Microradiographic analyses
Prior to scarifying the mice, ectopic bone formation in
the body was monitored by using a two-dimensional Soft
X-ray apparatus (Hitex Ltd, Osaka, Japan) and a diag-
nostic X-ray film (X-OMAT V, Kodak, Rochester, NY,
USA) under the following conditions; 35 kVp and
400 μA for 45 s. For three-dimensional analysis, each
isolated specimen was scanned by micro-computed tom-
ography (μ-CT; Skyscan 1172, Skyscan, Aartselaar,
Belgium) in cone-beam acquisition mode. The X-ray
source was set at 50 kV and 200 μA with a 0.5-mm
aluminum filter at 17.09 μm resolution. The exposure
time was 1.2 s and 257 projections were acquired over
an angular range of 180° (angular step; 0.7°). The image
slices were reconstructed by using the Nrecon program
(version 1.6.2.0, Skyscan, Aartselaar, Belgium) and bone
volume was measured using the CT-Analyzer program
(version 1.10.0.5, Skyscan, Aartselaar, Belgium). Three
dimensional surface rendering images were made using
the Mimics software version 14.0, imaging program
(Materialise N.V, Leuven, Belgium).
Histological analysis
All specimens were decalcified in a rapid decalcifying so-
lution (Calci-Clear Rapid, National Diagnostics, GA, USA)
for 10 days, and then embedded in paraffin and cut into
7-μm-thick serial slices. The sections were deparaffinized
in xylene at room temperature for 20 min and then rehy-
drated through a graded series of alcohol solutions. The
sections were then stained with hematoxylin and eosin.
Statistics analysis
All experiments were repeated at least three times
and statistical analysis was performed using one-way
analysis of variance and Duncan’s multiple compari-
sons using the Graph Pad Prism 4 for Windows stat-
istical software package (Graph Pad Software Inc., La
Jolla, CA, USA). All the data presented is expressed
as the mean ± SEM from three independent measure-
ments. A P-value < 0.05 was considered to be statisti-
cally significant.
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Results
BetA promotes osteogenic differentiation of MC3T3-E1
cells
Prior to in vivo study, we first examined the effects of
BetA on the cell viability and osteogenic differentiation
in MC3T3-E1 cells. Results showed that BetA treatment
at a concentration of up to 30 μM did not significantly
reduce cell viability compared to the control group
(Fig. 1a). Treatment with BetA, ranging from 5 to
15 μM, induced ALP activity and gene expression of the
osteogenic markers, ALP, BMP2, BSP and OC (Fig. 1b
and c). These results showed that although there was no
effect on the cell viability at the concentrations used,
BetA had the ability to promote osteogenesis.
Treatment with a combination of BetA and BMP2 further
enhances matrix mineralization
BMP2 is well known for its osteogenic properties and is
used clinically in the management of skeletal conditions
requiring bone anabolism [25, 26]. Moreover, treatment
with BetA potently increased the expression of BMP2 as
well as that of other osteogenic markers (Fig. 1c). To
further investigate the effects of BetA on BMP2-
stimulated osteogenesis, MC3T3-E1 cells were cultured
with BetA (10 μM) and/or BMP2 (200 ng/ml) for 10 days
in osteogenic medium, and then gene expressions and
matrix mineralization was analyzed. Results showed that
treatment with a combination of BetA with BMP2 syner-
gistically enhanced the gene expression of osteogenic
markers, ALP and OC (Fig. 2a). Matrix mineralization was
also significantly enhanced by a combination of BetA and
BMP2 compared with groups treated with either BetA or
BMP2 alone in a consistent fashion (Fig. 2b). These results
suggest that BetA had an effect on osteogenic differenti-
ation and greatly enhanced the BMP2-induced differenti-
ation and mineralization in these cells.
BetA enhances BMP2-dependent phosphorylation of
Smad, ERK and p38
The BMP/Runx2 signal pathway is involved in BetA-
mediated osteoblast differentiation [9]. Our results de-
scribed above showed that BetA significantly increased
BMP2-induced osteogenic differentiation (Fig. 2). In
order to investigate the intracellular signaling pathways
involved in this effect, we assessed whether BetA af-
fected the levels of phosphorylation of Smad1/5/8 and
MAPK (ERK and p38). Results showed that BetA
stimulated the phosphorylation of Smad1/5/8 by
about 1.5-2 fold compared to the control at 5 min
and 10 min, respectively and increased the phosphor-
ylation of p38 by about 0.4 fold compared with the
control group at 10 min (Fig. 3a, b and d). Treatment
with BMP2 treatment increased Smad1/5/8, ERK and
p38 phosphorylation by about 3, 0.4 and 0.8 fold
respectively at 5 min compared to the control. Treat-
ment with a combination of BetA and BMP2 further
enhanced the Smad1/5/8, ERK and p38 phosphoryl-
ation by about 4, 0.7 and 2 fold respectively at 5 min
compared to the control (Fig. 3b-d). These results
suggest that BetA could be a positive stimulator of
the BMP signaling pathway and can enhance BMP2-
induced osteogenic differentiation.
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Fig. 1 The effect of betulinic acid (BetA) on cell viability and osteogenic
differentiation in MC3T3-E1 preosteoblast cells. a Cell viability assay. The
MC3T3-E1 cells were cultured with different concentrations of BetA
(0 μM to 30 μM) for 24 h, and cell viability was determined by WST-1.
b ALP staining. The MC3T3-E1 cells were cultured in osteogenic medium
containing different concentrations of BetA (0 μM to 20 μM) for 72 h,
and then ALP staining was performed as in Materials and Methods. c RT-
PCR analysis. The MC3T3-E1 cells were cultured as in (b). Total RNA was
isolated and RT-PCR was performed with specific primers for ALP, BMP2,
BSP and OC. The level of GAPDH was examined as a loading control.
Representative data are shown. ALP, alkaline phosphatase. BSP, bone
sialoprotein. OC, osteocalcin. n= 3
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BetA can enhance BMP2-induced ectopic bone formation
Based on the beneficial effect of treatment with a com-
bination of BetA and BMP2 in vitro, we investigated
whether such treatment could promote bone formation
and improve callus bone parameters in vivo. In the
present study, the effect of BetA on BMP2-induced ec-
topic bone formation was evaluated in following groups;
control treatment (collagen sponge alone), BetA treat-
ment (25, 50 μg), BMP2 treatment (1 μg, 3 μg), and
combinational treatments of BetA/BMP2. BetA or/and
BMP2 were delivered into the subcutaneous space on
both sides of the backs of mice using an absorbable col-
lagen sponge. At 4 weeks after implantation, new bone
formation was analyzed by X-ray (2D) and high reso-
lution μ-CT (3D) scanning. As shown in Additional file
1: Figure S1 and S4, the control and BetA treatment did
not induce ectopic bone in the region of the implant. In
contrast, implantation of BMP2 (1 or 3 μg) alone
induced ectopic bone formation. In the group treated
with the BetA (25, 50 μg) with BMP2 (1 μg), the amount
of new bone tended to increase dependent on BetA
doses (Additional file 1: Figure S1C). In addition, treat-
ment with the combination of BetA (25, 50 μg) and
BMP2 (3 μg) resulted in a significant increase in the vol-
ume of ectopic bone formation compared to treatment
with BMP2 (3 μg) alone (Fig. 4c). Histological examin-
ation showed that the newly formed bone was an oval
shape of single mass. Mineralized tissue was observed
mostly at the periphery of the implants containing
BMP2 alone or the combined composites. No significant
adverse reaction observed in all groups (Fig. 5).
Discussion
BMP2 is crucial for the development, induction, and dif-
ferentiation of osteogenic cells as well as for the repair
of bone defects [13, 23, 27]. However, there are disad-
vantages to the use of BMP2 for bone repair, including
the high cost, rapid degradation, and edema [19, 20]. In
order to overcome these limitations, the possibility of
the use of a combination of BMP2 with biological or
chemical agents offers a new surgical approach that
might augment bone formation or even replace bone-
grafting procedures [13]. Molecules including oxysterols
[28], NELL1 [29], C-type natriuretic peptide [30], vascu-
lar endothelial growth factor (VEGF) [31], and parathy-
roid hormone-related peptide (PTHrP) [32] have been
shown to be either synergistic with or supportive of
BMP induction of osteogenic differentiation in vitro.
Furthermore, in vivo studies have also shown synergistic
enhancement in bone formation when BMPs are com-
bined with VEGF and NELL1 [29, 31]. BetA was also
reported to be a potent osteogenic molecule acting
through the BMP/Runx2 and β-catenin signaling path-
ways [9]. The present study was conducted to prove the
hypothesis that treatment with a combination of BetA
and BMP2 will be more effective for osteogenic differen-
tiation and bone formation than BMP2 treatment alone.
Our results showed that BetA increased the gene expres-
sion of osteogenic markers as well as ALP activity
(Fig. 1). Treatment with a combination of BetA and
BMP2 significantly increased osteogenic marker gene
expression and matrix mineralization compared to
treatment with BMP2 alone, indicating a synergistic
effect on osteogenic differentiation (Fig. 2) and
suggesting that BetA may influence BMP2 mediated
osteoblast functions.
In order to further understand the molecular mechan-
ism involved in BetA potentiation of BMP2 action, since
there are no known receptors for BetA, we investigated
the possibility that BetA may have an impact on signal-
ing pathways that can crosstalk with BMP signaling. The
phosphorylation of Smad1/5/8 and MAPK signaling
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Fig. 2 The effect of betulinic acid on BMP2-induced osteogenic
differentiation and matrix mineralization in MC3T3-E1 preosteoblast
cells. a RT-PCR analysis. The MC3T3-E1 cells were maintained with
osteogenic medium containing BetA (10 μM) and/or BMP2 (200 ng/ml)
for 10 days, and expression of osteogenic marker genes were measured
by RT-PCR. b Mineralization assay. Cells were cultured as in (a), and
were stained with alizarin red solution (upper panel). For quantification,
the stains were eluted with 10 % cetylpyridinium and absorbance was
measured by spectrophotometry (lower panel). *, p < 0.05 compared to
the indicated group. Representative data are shown. n= 3
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pathways, which have been shown to directly stimulate
bone formation and osteoblast differentiation, are usu-
ally triggered by BMPs [22, 24]. In the present study,
BetA treatment did indeed increase the phosphorylation
of Smad1/5/8, ERK and p38. Furthermore, combination
of BetA and BMP2 enhanced the Smad1/5/8 and p38
phosphorylation even more as compared with each one
alone (Fig. 3). These results suggest that BetA stimulates
the BMP2 action on osteogenic differentiation through the
Smad1/5/8 and p38 signaling pathways. However, we did
not identify yet whether BetA can affect BMP2-induced
bone formation via immobilizing the BMP2 in the absorb-
able collagen sponge, or via inhibiting the degradation of
BMP2, or via increasing binding of BMP2 to its receptors,
or via activating other signal pathways. Further studies are
still needed for determining the exact mechanism.
In this study, we have demonstrated for the first time
the effect of treatment with BetA and with a combin-
ation of BetA and BMP2 in an animal model. The
subcutaneous ectopic bone formation increased after
treatment with either BMP2 alone or with the combin-
ation of 25 μg BetA and 3 μg BMP2 in mice (Fig. 4).
The combination of BetA and BMP2 resulted in a bone
volume approximately 30 % higher than that observed
when BMP2 alone was used (Fig. 4c). Increasing the
concentration of BetA up to 50 μg under maintaining
BMP2 at 3 μg enhanced the volume of newly formed
bone by approximately 70 % compared to that observed
using 3 μg BMP alone (Fig. 4c). The data indicate that
BetA and BMP2 acts synergistically to induce more bone
formation than does BMP2 alone. However, when 25 or
50 μg of BetA was treated with 1 μg of BMP2, ectopic
bone formation merely tended to increase compared to
the BMP2 alone group; the differences between groups
did not reach statistical significance (Additional file 1:
Figure S1). These findings suggest that doses or ratio of
BetA and BMP2 combination would be also crucial for
synergistic bone formation in vivo.
The present study provides beneficial evidence that
combination of BetA and BMP2 can enhance osteogen-
esis. Nevertheless, there are some limitations in this
study that should be noted. First, combinatory effects of
BetA and BMP2 on bone formation were examined just
in an ectopic bone formation model. Because BetA and
BMP2 will be mostly applied to bony defects for the
purpose of therapy, the combinatory effects have to be
approved more in orthotopic bone formation models.
Second, our study did not determine the best dosage for
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Fig. 3 Effects of betulinic acid on phosphorylation of Smad, ERK and p38 in MC3T3-E1 cells. a Western blot analysis of phosphorylation of Smad,
ERK and p38 before and after BetA (10 μM) and/or BMP2 (200 ng/ml) for 5 to 10 min. b to d Quantitative analysis. Phosphorylation of Smad1/5/8,
ERK and p38 was quantified by using a LAS-4000 lumino-image analyzer system (Fujifilm, Japan). Each phosphorylation was normalized by the
total amount of Smad1 (b), ERK (c) and p38 (d). *, p < 0.05 compared to the control group. #, p < 0.05 compared to the indicated group. Represen-
tative data are shown. n = 3
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Fig. 5 Histological examination of the ectopic bone with treatments of betulinic acid (25 or 50 μg), BMP2 (3 μg), and the combination of BetA and
BMP2. All specimens used for radiographic analyses (Fig. 4) were formalin-fixed, paraffin-embedded and then cut into 7-μm-thick sections. The sections
were then stained with hematoxylin and eosin. Low panels show the magnifying images of the box areas in upper panels. New bones are observed in
BMP2- or BetA/BMP2-treated group as indicated with arrows. Microphotographs are shown at × 10 and × 100 magnification. n = 5
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combination, which might be significant to develop a
therapeutic strategy without dose-related side effects. In
addition, this study did not include the optimal timing
of application (sequential or simultaneous administra-
tion) and proper carriers. For therapeutic uses of the
combination, further studies are needed with more spe-
cific experimental conditions and various animal models.
Taken together, our results showed that BetA up-
regulates the expression of BMP2-induced osteogenic
marker genes and mineralized matrix deposition in pre-
osteoblastic cells, which results in augmentation of bone
formation through activating the Smad 1/5/8 and p38
signaling pathways. BetA could be described as a positive
stimulator for BMP2-induced ectopic bone formation.
Conclusions
In order to improve the bone formation by BMPs, sev-
eral scientists have investigated the use of BMPs in com-
bination with other agents. The present study, using the
ectopic bone formation model, indicates that BetA acts
synergistically with BMP2 to accelerate bone formation.
Thus, combination therapy with BetA and BMP2 may
be of great benefit in fracture healing and for patients
undergoing reconstructive surgery.
Additional files
Additional file 1: Figure S1. Radiographic study of the ectopic bone
formation after treatment of BetA, low dose of BMP2 and BetA/BMP2.
BetA (25 and 50 μg) with or without BMP2 (1 μg) was administered with
absorbable collagen sponges into the subcutaneous spaces in the back
of mice, as in Fig. 4. After 4 weeks, ectopic bone formation was analyzed by
Soft X-ray (A), μ-CT (B), and quantified by using a CT-Analyzer program (C).
Dotted circles in (A) indicate the new ectopic bones. **, p < 0.01 compared to
the control group (collagen sponge alone). NS, not significant. Representative
data are shown. n= 5. (PDF 114 kb)
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